Informações:
Falhas:
ID
17219
Descrição
A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00517283
Link
https://clinicaltrials.gov/show/NCT00517283
Palavras-chave
Versões (1)
- 01/09/2016 01/09/2016 -
Transferido a
1 de setembro de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Type 2 Diabetes Mellitus NCT00517283
Eligibility Type 2 Diabetes Mellitus NCT00517283
- StudyEvent: Eligibility
Similar models
Eligibility Type 2 Diabetes Mellitus NCT00517283
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Type 2 diabetes mellitus
Item
subjects with at least 1 year history of type 2 diabetes mellitus.
boolean
C0011860 (UMLS CUI [1])
HbA1C
Item
subjects controlled by oral antidiabetic agents or diet and exercise demonstrated by a screening hba1c ≥7.0% and ≤10.0%.
boolean
C0202054 (UMLS CUI [1])
BMI
Item
between the body mass index (bmi) of 19 kg/m2 and 40 kg/m2, inclusive.
boolean
C1305855 (UMLS CUI [1])
Investigational Drugs
Item
within 4 months of the initial dose of study drug, have received a drug that has not received regulatory approval for any indication.
boolean
C0013230 (UMLS CUI [1])
Study Subject Participation Status
Item
persons who have previously completed or withdrawn from this study or any other study investigating exenatide.
boolean
C2348568 (UMLS CUI [1])
drugs affecting gastrointestinal motility
Item
subjects who are using drugs that significantly affect gastrointestinal motility (including acarbose, metoclopramide, and macrolide antibiotics).
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0017184 (UMLS CUI [1,3])
C0392760 (UMLS CUI [1,2])
C0017184 (UMLS CUI [1,3])
Concomitant medication
Item
subjects who intend to start new concomitant medication during the study, including over-the counter medication, apart from occasional intake of paracetamol or vitamin/mineral supplements. anti-emetic medication may be permitted at the investigator's discretion, except those that affect gastrointestinal motility.
boolean
C2347852 (UMLS CUI [1])
Insulin
Item
subjects who have used insulin for more than 4 weeks within 3 months prior to screening.
boolean
C0021641 (UMLS CUI [1])
blood donation
Item
blood donation of more than 500 ml in the last 3 months of screening or any blood donation within the last month.
boolean
C0005794 (UMLS CUI [1])